Luteinizing Hormone Releasing Hormone

Phase 3Small molecule

Luteinizing Hormone Releasing Hormone is one of 77 small molecule programs targeting Spinal Cord Injury. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal Cord InjuryActive, not recruiting

Prostate CancerTerminated

Spinal Cord InjuryPreclinical

Active, not recruiting

Prostate CancerPhase 3

Terminated

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 2

Glucophage

EMD Serono

Phase 3

14 3

Acetylsalicylic Acid

Bayer

Phase 3

2 4

Perflutren Lipid Microspheres

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 3

1 5

Piflufolastat

Novartis

Phase 3

2 6

PSMA-1007

AABX advanced biochemical compounds GmbH

Phase 3

3 7

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 8

Florastamin

HHTA Co., Ltd.

Phase 3

2 9

Trexall

Jazz Pharmaceuticals

Preclinical

—10

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Active, not recruiting

Prostate Cancer

NCT05189457

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

Terminated·PProton Collaborative Group·Phase 2/3·NCT01603420·2 enrolled

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT05189457·32 enrolled

Spinal Cord Injury1 trial

Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.

Completed·UUS Department of Veterans Affairs·N/A·NCT00223860·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Luteinizing Hormone Releasing Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Luteinizing Hormone Releasing Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Luteinizing Hormone Releasing Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — US Department of Veterans Affairs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUS Department of Veterans Affairs

Luteinizing Hormone Releasing Hormone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Prostate Cancer2 trials

Spinal Cord Injury1 trial

References

Drug Info

Quick Facts

Related News